1. Pharmacology, Dilution & 0.22 µm In-Line Filtration
Infliximab is a chimeric IgG1κ monoclonal antibody directed against tumor necrosis factor-alpha (TNF-α), widely indicated in Crohn's disease, Ulcerative Colitis, Rheumatoid Arthritis, and Ankylosing Spondylitis. Safe compounding and preparation require strict clinical procedures:
- Reconstitute each 100 mg vial with 10 mL of Sterile Water for Injection using a 21-gauge or smaller needle.
- Do NOT shake the vial. Gently swirl the solution until dissolved. Vigorous shaking causes foaming and protein denaturation, generating bioactive immunogenic protein aggregates.
- Dilute the calculated dose in 250 mL of 0.9% Normal Saline.
- Mandatory In-Line Filtration: Administration must utilize an in-line, sterile, non-pyrogenic, low-protein-binding 0.22 µm membrane filter (polyethersulfone or PVDF) to eliminate sub-visible protein aggregates without stripping active antibody molecules from the infusate.
2. Standard Rate Escalation Protocol
Standard induction infusions take place over 2 hours via smart infusion pump rate titration:
- 0 – 15 min: 10 mL/h
- 15 – 30 min: 20 mL/h
- 30 – 45 min: 40 mL/h
- 45 – 60 min: 80 mL/h
- 60 – 105 min: 150 mL/h
- 105 – 120 min: 250 mL/h over remainder of dose
Accelerated 1-hour maintenance infusions are restricted exclusively to adult patients who have safely tolerated at least 3 consecutive 2-hour maintenance infusions without any acute reaction history.
3. Acute Infusion Reactions vs. Delayed Serum Sickness
Infusion reactions to infliximab manifest across two distinct immunological timelines:
| Reaction Type | Onset Window | Clinical Presentation | Immediate Bedside Interventions | Future Re-Challenge |
|---|---|---|---|---|
| Mild Acute | During infusion (<2 h) | Transient flushing, low fever, localized itching | Reduce rate by 50%; oral diphenhydramine and acetaminophen | Yes (with premed) |
| Moderate Acute | During infusion (<2 h) | Urticaria, chest tightness, palpitations, mild dyspnea | Halt infusion; IV diphenhydramine 50 mg + hydrocortisone 100 mg; resume at 50% upon resolution | Yes (slow titration) |
| Severe Anaphylaxis | First 10 – 30 min | Stridor, acute bronchospasm, SBP drop > 30 mmHg, shock | Terminate infusion permanently; Epinephrine 0.3 mg IM; 100% O2; IV saline bolus | Contraindicated |
| Delayed Serum Sickness | 3 – 12 days post-infusion | Polyarthralgia, myalgias, fever, rash, facial swelling | Oral prednisone (0.5 mg/kg/day x 5-7 days), NSAIDs; check anti-infliximab antibodies (ATI) | Evaluate switch to humanized biologic |